

## AMENDMENTS

### Listing of Claims:

The following listing of claims replaces all previous listings or versions thereof:

- 1 – 19. (Canceled)
20. (Previously presented) A method of inhibiting angiogenesis in a human individual comprising the step of administering a Corticotropin Releasing Factor Receptor 2 (CRFR2) agonist to said individual; wherein if the individual has cancer, then the method further comprises determining whether angiogenesis has been inhibited in said individual.
21. (Previously presented) The method of claim 20 wherein said CRFR2 agonist is selected from the group consisting of urocortin and corticotropin releasing factor.
22. (Previously presented) The method of claim 20, wherein said CRFR2 agonist inhibits angiogenesis in a tissue selected from the group consisting of heart, brain, pituitary, gonad, kidney, adipose, and gastrointestinal tract tissues.
23. (Previously presented) The method of claim 20, wherein said angiogenesis is inhibited in an individual having cancer.
- 24 – 27. (Canceled)
28. (Previously presented) The method of claim 20, wherein said angiogenesis is inhibited in an individual having a pathophysiological condition which is not cancer.
29. (Previously presented) The method of claim 24, wherein said pathophysiological condition is a diabetic retinopathy.

30. (Previously presented) The method of claim 24, wherein the method further comprises determining whether angiogenesis has been inhibited in said individual.